Wenxiu Yao

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Jie Wang, Caicun Zhou, Wenxiu Yao et al. · The Lancet Oncology · 2022 · 395 citations

Medicine, Oncology, Pharmacology +11

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Shengxiang Ren, Jianhua Chen, Xingxiang Xu et al. · Journal of Thoracic Oncology · 2021 · 313 citations

Medicine, Oncology, Pharmacology +6

Liposomal Quercetin Efficiently Suppresses Growth of Solid Tumors in Murine Models

Zhiping Yuan, Lijuan Chen, Linyu Fan et al. · Clinical Cancer Research · 2006 · 251 citations · Full text

Medicine, Oncology, Pharmacology +14

Repotrectinib in <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer

Alexander Drilon, D. Ross Camidge, Sang‐We Kim et al. · New England Journal of Medicine · 2024 · 210 citations · Full text

Medicine, Oncology, Pharmacology +16

Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)

Hongyun Zhao, Wenxiu Yao, Xuhong Min et al. · Journal of Thoracic Oncology · 2021 · 121 citations · Full text

Medicine, Oncology, Pharmacotherapy +8